An interventional study of EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS) and Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD) and Treatment Resistant Obsessive Compulsive Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Obsessive-Compulsive Disorder with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Canada.
Among the 52 studies in Obsessive-Compulsive Disorder with a site in Canada, this one is the 21st largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2025, is one of 33 with no phase, reaches primary completion later than 13 of the 15 other live ones, and was the 48th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →12 of the 52 studies in Obsessive-Compulsive Disorder with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–85
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
University of Manitoba · Sites in Canada
Ages 6–24
Ciusss de L'Est de l'Île de Montréal · Sites in Canada
Ages 18+
Valerie Taylor · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is close to the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 39 across the 47 interventional studies, 160 across the 5 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 52 have an industry lead sponsor. The 10 most frequent:
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
Centre for Addiction and Mental Health has 4 studies filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Obsessive-Compulsive Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01635569University of British ColumbiaClinical Outcomes in Pediatric Obsessive-Compulsive Disorder | 2027-06 |
| NCT07704632Sunnybrook Health Sciences CentreSafety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Obsessive-Compulsive Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial aims to obtain initial evidence about the clinical efficacy and modulation of neurophysiological markers in obsessive compulsive disorder (OCD) using personalized (i.e., electroencephalography (EEG)-triggered) repetitive transcranial magnetic stimulation (rTMS) as compared to non-personalized (i.e., non-EEG triggered), standard rTMS applied to the dorsomedial prefrontal cortex.
This trial uses a prospective, randomized, single-blind study design with two treatment arms at the Centre for Addiction and Mental Health (CAMH) in Toronto, ON, Canada. The study aims to compare the clinical effects of EEG-triggered, personalized rTMS (i.e., experimental arm) in the treatment of OCD to those of non-EEG triggered, non-personalized rTMS (i.e., active-comparator arm). Additionally, the study aims to compare the modulation of neurophysiological (i.e., EEG) markers of OCD between the two arms.
Study treatment will be administered five days per week across a six-week treatment course for a total of 30 sessions. Both rTMS arms will use the same TMS coil, stimulation intensity, number of pulses, and anatomical target (i.e., dorsomedial prefrontal cortex).
Clinical outcomes will be measured using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) with clinical response defined as a ≥30% improvement on the Y-BOCS. The self-reported revised Obsessive Compulsive Inventory (OCI-R) and Clinical Global Impressions - Improvement (CGI-I) scale will also be used. Neurophysiological outcomes will be measured by the change in frontoparietal theta amplitude (i.e., 4-7 Hz) and power of TMS-induced theta oscillations.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)
Device: Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)
The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. EEG data will be analyzed in real-time using the bossdevice MEDICAL and TMS pulses will be synchronized to the negative peak of the frontoparietal theta oscillation. 500 consecutive EEG theta-oscillation negative-peak triggered quadruplet bursts with a 5ms inter-pulse-interval will be applied at a median inter-burst interval of 2-3s. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 15-30 minutes.
Also known as: Personalized rTMS, EEG-triggered rTMS, Personalized TMS, EEG-triggered TMS
The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. High-frequency rTMS consisting of 50 trains at 20 Hz (2s on, 18s off) will be delivered. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 15-30 minutes.
Also known as: Standard rTMS, Standard TMS, rTMS, TMS
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
The Y-BOCS is used to (a) qualify OCD symptoms using a symptom checklist and (b) assess their severity using a symptom severity rating scale. The checklist allows the participant to identify the thoughts and behaviours that are part of their OCD. The severity scale assesses five dimensions of obsessions and compulsions: time spent or occupied, interference with functioning or relationships, degree of distress, resistance, and control (i.e., success with resistance). The scale ranges from 0-40; a lower score indicates less severe OCD, while a higher score indicates more severe OCD.
Time frame: From screening to the end of the follow-up period (1-month post-intervention)
Obsessive Compulsive Inventory - Revised (OCI-R)
The OCI-R is a self-reported 18-item scale that measures symptom severity across six domains of OCD: washing, checking, ordering, neutralizing, obsessing, and hoarding. The scale ranges from 0-72; lower scores indicate less severe OCD (or a subclinical presentation for scores \<21), while higher scores indicate more severe OCD.
Time frame: From screening to the end of the follow-up period (1-month post-intervention)
Clinical Global Impressions - Improvement (CGI-I) Scale
The CGI-I is a clinician-determined assessment that rates change in global clinical presentation (i.e., improvement or worsening) from the baseline presentation on a 7-point scale.
Time frame: From screening to the end of the follow-up period (1-month post-intervention)
Electroencephalography (EEG) Markers of OCD
1. Amplitude of frontoparietal theta oscillations in the resting EEG before and after single treatment sessions measured in dB 2. the power of TMS-induced oscillations in the theta range throughout the six-week treatment course measured in dB
Time frame: From screening to the end of the follow-up period (1-week post-intervention)
Plan to share: Yes — De-identified data from this project may be used for future research by internal and/or external project collaborators upon participant consent.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 48 months is above that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
Centre for Addiction and Mental Health →